英国NICE卫生技术评估公众参与机制及启示

金秋晨; 李梦颖; 陈永法

doi:10.6039/j.issn.1001-0408.2023.11.04

您当前的位置：

首页 >

文章列表页 >

英国NICE卫生技术评估公众参与机制及启示

药事管理 | 更新时间：2023-06-09

- 英国NICE卫生技术评估公众参与机制及启示
- Mechanism and enlightenment of public participation in the NICE health technology assessment in England
- 中国药房 2023年34卷第11期页码：1302-1306
- 作者机构：
  
  中国药科大学国际医药商学院，南京　211198
- 作者简介：
  
  硕士研究生。研究方向：医药政策与药物经济学评价。E-mail：cathieee@outlook.com
  教授，博士生导师，博士。研究方向：国内外药事法规与药品评价。E-mail：cyf990@163.com
- 基金信息：
  
  2020年江苏省研究生科研创新计划项目（No.KYCX20＿0697）
- DOI：10.6039/j.issn.1001-0408.2023.11.04
  中图分类号： R95
- 纸质出版日期：2023-06-15，
  
  收稿日期：2022-12-11，
  
  修回日期：2023-04-03，
扫描看全文
金秋晨,李梦颖,陈永法.英国NICE卫生技术评估公众参与机制及启示 ^Δ[J].中国药房,2023,34(11):1302-1306.

JIN Qiuchen,LI Mengying,CHEN Yongfa.Mechanism and enlightenment of public participation in the NICE health technology assessment in England[J].ZHONGGUO YAOFANG,2023,34(11):1302-1306.
金秋晨,李梦颖,陈永法.英国NICE卫生技术评估公众参与机制及启示 ^Δ[J].中国药房,2023,34(11):1302-1306. DOI： 10.6039/j.issn.1001-0408.2023.11.04.

JIN Qiuchen,LI Mengying,CHEN Yongfa.Mechanism and enlightenment of public participation in the NICE health technology assessment in England[J].ZHONGGUO YAOFANG,2023,34(11):1302-1306. DOI： 10.6039/j.issn.1001-0408.2023.11.04.

摘要

目的

深入剖析英国国家卫生与服务优化研究院（NICE）卫生技术评估公众参与机制，以期为我国医保目录动态调整工作提供经验借鉴。

方法

检索相关文献及官方网站，对英国NICE卫生技术评估公众参与类型、参与机制（管理机构、遴选方式、参与模式、评估反馈）进行分析，并据此提出对我国医保目录调整公众参与的建议。结果与

结论

当前NICE卫生技术评估公众参与类型主要涉及患者及照护者组织、评估委员会非专业成员、患者专家、公众观察员4类。在管理层面，NICE设立了公众参与团队并制定了有关公众参与事项的指南；针对不同类型公众，NICE确定了兴趣表达、NICE邀请、公开招聘、提名、NICE决定等不同的遴选程序；公众参与的类型多样，且从卫生技术评估最初的主题范围确定到最终的上诉，全程均有公众的参与；建立了灵活动态的评估反馈体系以优化公众参与的方式和卫生技术评估流程；开展了广泛的国际合作与交流以促进国家和国际层面的公众参与。建议我国结合国情，明确公众参与卫生技术评估的渠道，成立公众参与事务工作小组，加强患者参与评估与反馈，提高决策透明度，从渠道开设、管理机制、评估反馈、信息公开等方面不断完善我国卫生技术评估公众参与机制。

Abstract

OBJECTIVE

To analyze the public participation mechanism of National Institute for Health and Care Excellence （NICE） health technology assessment in England and to provide experience for the dynamic adjustment of Chinese medical insurance catalog.

METHODS

By retrieving related literature and official websites， types and mechanisms of public participation （management organization， selection method， participation mode， evaluation feedback） in NICE health technology assessment were analyzed comprehensively； and based on this， suggestions were put forward to adjust the public participation in Chinese medical insurance catalog.

RESULTS &

CONCLUSIONS

The current public participation types of NICE health technology assessment were patient and carer organizations， HTA committee lay members， patient expert and public observers. At the management level， NICE has set up a public participation team and made guidelines on public participation matters. For different public participation types， NICE has established different selection procedures， such as expression of interest， NICE invitation， open recruitment， nomination， NICE decision， etc. The public participation types are various and in the whole assessing process from the initial determination of the scope of the health technology assessment to the final appeal. Also， NICE has established a flexible and dynamic evaluation feedback system to optimize the way of public participation and the health technology assessment process； NICE has undertaken extensive international cooperation and exchanges to promote public participation at the national and international levels. It is suggested that our country should combine the national conditions， clarify the channel of public participation in health technology evaluation， set up a working group of public participation affairs， strengthen patients’ participation in evaluation and feedback， improve decision-making transparency， and improve the public participation mechanism of health technology evaluation from the aspects of channel opening， management mechanism， evaluation feedback， information disclosure and so on.

关键词

卫生技术评估公众参与英国国家卫生与服务优化研究院启示

Keywords

public participationNational Institute for Health and Care Excellence in Englandenlightenment

references

岳晓菲，张帆，刘跃华，等. 英国NICE卫生技术评估流程的决策转化机制及启示[J]. 中国卫生经济，2021，40（1）：91-96.

刘世蒙，杨毅，孙辉，等. 患者偏好证据应用于卫生技术评估的价值、方法及挑战[J]. 中国卫生政策研究，2022，15（5）：52-58.

吴晶.卫生技术评估为医保目录调整提供决策依据[EB/OL]. （2022-01-30）[2022-11-10]. https：//www.cn-healthcare.com/articlewm/20220127/content-1310243.htmlhttps://www.cn-healthcare.com/articlewm/20220127/content-1310243.html.

肖月. 英国国家卫生与服务优化研究院的卫生技术评估模式与经验分析[J]. 医学与社会，2022，35（8）：1-8.

涂正革，邓辉，甘天琦. 公众参与中国环境治理的逻辑：理论、实践和模式[J]. 华中师范大学学报（人文社会科学版），2018，57（3）：49-61.

石震，王铭敏. 健康治理中公众参与的行为逻辑与路径构建[J]. 中国农村卫生事业管理，2021，41（7）：487-491.

李鸻. 政策形成过程中的公众参与：以中国医疗政策改革为例[J]. 华东政法大学学报，2014，17（3）：96-105.

National Institute for Health and Care Excellence. Patient and public involvement policy [EB/OL]. （2013-11-01）[2022-11-10].https：//www.nice.org.uk/about/nice-communities/nice-and-the-public/public-involvement/public-involvement-programme/patient-public-involvement-policyhttps://www.nice.org.uk/about/nice-communities/nice-and-the-public/public-involvement/public-involvement-programme/patient-public-involvement-policy.

ARNSTEIN S. A ladder of citizen participation[J]. J Am Plan Assoc，2019，85（1）：24-34.

吕兰婷，傅金澜，王汐. 以患者为中心的卫生决策体系构建：基于个体与全民水平的思考[J]. 中国医院管理，2021，41（12）：41-46.

杨正，肖遥. 为何要引入公众参与科学：公众参与科学的三种逻辑：规范性、工具性与实质性[J]. 科学与社会，2021，11（1）：115-136.

HOGG C，WILLIAMSON C. Whose interests do lay people represent? Towards an understanding of the role of lay people as members of committees[J]. Health Expect，2001，4（1）：2-9.

LITTLEJOHNS P. Patient involvement in NICE techno- logy appraisals[M]. London：Radcliffe Publishing，2018：29-38.

National Institute for Health and Care Excellence. Guide to the processes of technology appraisal[EB/OL]. [2022-11-10]. https：//www.nice.org.uk/process/pmg19/chapter/introductionhttps://www.nice.org.uk/process/pmg19/chapter/introduction.

National Institute for Health and Care Excellence. Public Involvement Programme[EB/OL]. [2022-11-10]. https：//www.nice.org.uk/about/nice-communities/nice-and-the-public/public-involvement/public-involvement-programmehttps://www.nice.org.uk/about/nice-communities/nice-and-the-public/public-involvement/public-involvement-programme.

National Institute for Health and Care Excellence. NICE’s approach to public involvement in guidance and standards：a practical guide[EB/OL]. [2022-11-10]. https：//www.nice.org.uk/media/default/About/NICE-Communities/Public-involvement/Public-involvement-programme/PIP-process-guide-apr-2015.pdfhttps://www.nice.org.uk/media/default/About/NICE-Communities/Public-involvement/Public-involvement-programme/PIP-process-guide-apr-2015.pdf.

National Institute for Health and Care Excellence. Mee- tings in public[EB/OL]. [2022-11-10]. https：//www.nice.org.uk/Get-Involved/Meetings-in-public#advisory-committeehttps://www.nice.org.uk/Get-Involved/Meetings-in-public#advisory-committee.

NORBURN L，THOMAS L. Expertise，experience，and excellence. Twenty years of patient involvement in health technology assessment at NICE：an evolving story[J]. Int J Technol Assess Health Care，2020，37：e15.

National Institute for Health and Care Excellence. Public involvement at NICE：annual report 2019/2020[R/OL]. London：NICE，2020[2023-02-05]. https：//www.downtownaustin.com/annual-report-2020/https://www.downtownaustin.com/annual-report-2020/.

National Institute for Health and Care Excellence. Nin- tedanib for treating idiopathic pulmonary fibrosis in people with a forced vital capacity above 80% predicted[EB/OL]. （2023-02-01） [2023-02-05]. https：//www.nice.org.uk/guidance/ta864/evidence/committee-papers-pdf-1136951- 3773https://www.nice.org.uk/guidance/ta864/evidence/committee-papers-pdf-1136951-3773.

National Institute for Health and Care Excellence. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis[EB/OL]. （2015-09-11） [2023-02-05].https：//www.nice.org.uk/guidance/ta383/documents/ankylosing-spondylitis-and-axial-spondyloar- thritis-nonradiographic-adalimumab-etanercept-infliximab- and-golimumab-inc-rev-ta143-and-ta233-id694-appraisal-consultation-document2https://www.nice.org.uk/guidance/ta383/documents/ankylosing-spondylitis-and-axial-spondyloar-thritis-nonradiographic-adalimumab-etanercept-infliximab-and-golimumab-inc-rev-ta143-and-ta233-id694-appraisal-consultation-document2.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

国外药品生产远程检查模式介绍及启示

台湾地区医院药学模式介绍及对大陆地区的启示

国外客观结构化临床考试在药学临床技能评估中的应用及对我国的启示

CAR-T产品医保准入风险分担协议的国际经验及启示

美国Medicaid项目处方药费用控制措施介绍及对我国的启示